Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus Clinical research trials and A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus. A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus clinical trial. Subjects frequently obtain the most expert healthcare possible for their A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.

Home > "A" Clinical Trials Conditions > A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus

A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus



A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus

For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: To evaluate the safety and effectiveness of Retrovir (AZT) when used as prophylaxis for health care workers at risk for HIV infection from exposure to HIV-contaminated blood or blood components.
Details:
Eligibility:
Study Type:  Interventional, Treatment, Placebo Control
Minimum Age/Maximum Age: 13 Years/
Genders: Both
Protocol Entry Criteria: Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - A prior history of a malignancy other than cutaneous basal cell or cervical carcinomas. - Other significant, chronic underlying medical illness which, in the physician's judgment, would impair study completion. - Evidence of compromised bone marrow function (lab results) with a blood transfusion within the last month. - Liver dysfunction as indicated by lab results. Patients are excluded if there is a prior diagnosis of HIV infection by one of the following criteria: - HIV antibody positive by ELISA and Western blot assays or by other certified test method. (Patients who are ELISA positive but Western blot or other confirmatory tests are negative may continue in study). - HIV antigen positive. - Clinical symptoms which lead to a diagnosis by a licensed physician of AIDS or AIDS related complex or AIDS-related dementia. Also excluded are individuals who have experienced similar HIV exposure as described in this protocol in the past month and individuals who have previously been enrolled in this study. The purpose of these exclusions is to eliminate possible seroconversion in an individual that could be attributed to HIV exposure other than the single exposure experienced just prior to entry into the study. Prior Medication: Excluded within 4 weeks of study entry: - Any potentially myelosuppressive drug. - Nephrotoxic agent. - Other experimental therapy. Exposure of a health care worker to HIV-contaminated blood or blood component within 5 days prior to beginning therapy, defined as one of the following: - Penetrating wound from needle recently removed from patient or sample container (e.g., blood bag, blood tube) or from sharp object visibly contaminated with HIV-positive blood or blood component. In the case of needlesticks or cuts with sharp objects, blood or blood component must not have been exposed to the air for more than 1 hour. If actual infusion of blood occurs, the 1-hour time limit does not apply. - Hypodermic needles should come in contact with the blood and blood component from an HIV source but need not be visibly contaminated with blood to be considered a source of contamination. - Significant exposure to HIV-positive blood or blood component as the result of splash on abraded skin. - Significant exposure to HIV-positive blood or blood component as the result of splash on mucous membranes. - Participant must be able to give informed consent. Active drug or alcohol abuse sufficient in the physician's opinion to prevent compliance with the study regimen.
Total Enrollment: 

Location and Contact Information:

Glaxo Wellcome Inc
Research Triangle Park,  North Carolina,  27709
United States
 


Additional Information:
Study ID Numbers:  014I;  20
Study Start Date: 
Record last reviewed: August 1989
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002287

Other Hiv Infections Studies:
1. A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3

2. A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium avium Complex (MAC) and Fungal Infections in HIV-Infected Patients

3. The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

4. Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection

5. A Phase I/II Study of Recombinant Interleukin-4 in AIDS and Kaposi's Sarcoma

Related Studies:

Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Research Triangle Park Clinical Trials

A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the Virus
Modify your Search

  Other HIV Infections Clinical Trials
  Other North Carolina Clinical Trials
  Other Research Triangle Park Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103